Catalina Capital Group LLC Reduces Holdings in Stryker Co. (NYSE:SYK)

Catalina Capital Group LLC cut its position in Stryker Co. (NYSE:SYK) by 1.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,978 shares of the medical technology company’s stock after selling 27 shares during the quarter. Catalina Capital Group LLC’s holdings in Stryker were worth $712,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in SYK. Zhang Financial LLC boosted its holdings in Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after purchasing an additional 40,784 shares during the last quarter. Dale Q Rice Investment Management Ltd purchased a new position in shares of Stryker during the 4th quarter valued at approximately $587,000. Berkshire Bank grew its position in shares of Stryker by 13.8% during the fourth quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock worth $3,056,000 after buying an additional 1,030 shares in the last quarter. PFW Advisors LLC bought a new stake in shares of Stryker in the fourth quarter worth $1,350,000. Finally, Traynor Capital Management Inc. bought a new position in Stryker during the 4th quarter valued at $324,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on SYK shares. Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Barclays raised their target price on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a report on Thursday. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group increased their target price on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $419.37.

Stryker Stock Up 0.1 %

NYSE SYK opened at $390.90 on Monday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a market capitalization of $149.02 billion, a P/E ratio of 50.37, a PEG ratio of 2.78 and a beta of 0.96. The company’s 50 day simple moving average is $376.68 and its 200 day simple moving average is $363.02. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 EPS. Equities research analysts expect that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a $0.84 dividend. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.